TherapeuticsMD (NASDAQ:TXMD) Hits New 52-Week Low at $2.89

Share on StockTwits

TherapeuticsMD Inc (NASDAQ:TXMD) reached a new 52-week low during trading on Monday . The company traded as low as $2.89 and last traded at $2.91, with a volume of 132824 shares. The stock had previously closed at $3.15.

A number of equities research analysts have commented on TXMD shares. restated a “buy” rating and set a $14.00 target price on shares of TherapeuticsMD in a research note on Tuesday, February 12th. ValuEngine cut shares of TherapeuticsMD from a “buy” rating to a “hold” rating in a research note on Wednesday, February 20th. Zacks Investment Research cut shares of TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Thursday, February 28th. BidaskClub upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. Finally, Oppenheimer restated a “buy” rating on shares of TherapeuticsMD in a research note on Tuesday, March 19th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $9.41.

The stock has a market cap of $759.85 million, a PE ratio of -4.17 and a beta of 2.14. The company has a debt-to-equity ratio of 1.26, a quick ratio of 3.28 and a current ratio of 3.39.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.01. The firm had revenue of $3.95 million for the quarter, compared to analysts’ expectations of $5.96 million. TherapeuticsMD had a negative net margin of 907.71% and a negative return on equity of 159.71%. The company’s revenue for the quarter was up 4.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.11) earnings per share. As a group, equities analysts expect that TherapeuticsMD Inc will post -0.64 earnings per share for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co NY boosted its stake in shares of TherapeuticsMD by 8.2% during the first quarter. Metropolitan Life Insurance Co NY now owns 60,906 shares of the company’s stock valued at $296,000 after purchasing an additional 4,627 shares during the period. FMR LLC boosted its stake in shares of TherapeuticsMD by 0.5% during the first quarter. FMR LLC now owns 18,178,211 shares of the company’s stock valued at $88,527,000 after purchasing an additional 89,870 shares during the period. Daruma Capital Management LLC boosted its stake in shares of TherapeuticsMD by 11.8% during the first quarter. Daruma Capital Management LLC now owns 7,111,035 shares of the company’s stock valued at $34,631,000 after purchasing an additional 750,235 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of TherapeuticsMD by 41.6% during the first quarter. Goldman Sachs Group Inc. now owns 704,516 shares of the company’s stock valued at $3,431,000 after purchasing an additional 206,907 shares during the period. Finally, Ellington Management Group LLC purchased a new stake in shares of TherapeuticsMD during the first quarter valued at $142,000. Hedge funds and other institutional investors own 78.93% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4369681/therapeuticsmd-nasdaqtxmd-hits-new-52-week-low-at-2-89.html.

TherapeuticsMD Company Profile (NASDAQ:TXMD)

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

Further Reading: How Do Mutual Funds Work?

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Barry Zwarenstein Sells 7,663 Shares of Five9 Inc  Stock
Barry Zwarenstein Sells 7,663 Shares of Five9 Inc Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc  Stock
Venture Fund Vii L.P. Arch Sells 63,000 Shares of Syros Pharmaceuticals Inc Stock
Insider Selling: Neogen Co.  Director Sells 5,000 Shares of Stock
Insider Selling: Neogen Co. Director Sells 5,000 Shares of Stock
Neogen Co.  Director Sells $314,650.00 in Stock
Neogen Co. Director Sells $314,650.00 in Stock
Insider Selling: Airgain Inc  CEO Sells 22,464 Shares of Stock
Insider Selling: Airgain Inc CEO Sells 22,464 Shares of Stock
Insider Selling: Bottomline Technologies  Insider Sells 9,925 Shares of Stock
Insider Selling: Bottomline Technologies Insider Sells 9,925 Shares of Stock


© 2006-2019 Ticker Report